What Is Semaglutide? A Physician-Written Overview

Semaglutide is the active ingredient in Ozempic and Wegovy and is one of the most clinically studied weight loss medications available. It belongs to a broader class of GLP-1 receptor agonists used in physician-supervised weight loss programs. This article explains what semaglutide is, how it works in the body, what the trial evidence shows, and what to discuss with a physician before considering it.

What semaglutide is

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics GLP-1, a naturally occurring hormone the gut produces in response to food. Activating GLP-1 receptors reduces appetite, slows gastric emptying, and improves glucose-dependent insulin secretion. Originally approved as Ozempic for Type 2 diabetes, semaglutide was later approved as Wegovy for chronic weight management based on the strength of weight loss observed in trials.

How semaglutide works for weight loss

Semaglutide does not suppress appetite through stimulant effects. It recalibrates the hormonal signals that govern hunger and satiety. With sustained activation of GLP-1 receptors, hunger drops, meals feel more satisfying, gastric emptying slows so fullness lasts longer, and the background "food noise" that many patients describe diminishes. The net effect is a physiological reduction in caloric intake without willpower-based restriction.

What the STEP and SELECT trials show

The STEP clinical trial program demonstrated average weight loss of approximately 14.9 percent of body weight over 68 weeks at the 2.4mg weekly maintenance dose, compared with 2.4 percent on placebo. STEP 4 confirmed the medication's role in chronic management: patients who continued semaglutide maintained their weight loss, while those switched to placebo regained significant weight. The SELECT trial went further, showing semaglutide reduced major cardiovascular events (heart attack, stroke) by 20 percent in adults with obesity and established cardiovascular disease. Individual results vary by starting weight, adherence, lifestyle, and metabolic response.

Dosing and titration

Semaglutide is administered as a weekly subcutaneous injection in the abdomen, thigh, or upper arm. It follows a gradual titration schedule to improve tolerability and reduce GI side effects during dose escalation. A standard schedule is 0.25mg weekly for weeks 1 to 4, 0.5mg for weeks 5 to 8, 1mg for weeks 9 to 12, 1.7mg for weeks 13 to 16, and 2.4mg weekly at maintenance. Titration may be slower based on individual tolerability and provider judgment. Not every patient needs to reach maximum dose; many achieve excellent results at intermediate doses with better tolerability.

Common side effects and safety considerations

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. They are typically most pronounced during titration and usually improve over time. Slower titration, smaller meals, lower-fat eating, and adequate hydration meaningfully reduce GI burden for most patients.

Less common but serious considerations include pancreatitis (rare, presenting as severe persistent abdominal pain) and gallbladder disease, which is more common during rapid weight loss. Semaglutide carries a black box warning for thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. It is not appropriate during pregnancy. A qualified physician screens for these contraindications before prescribing.

What patients typically experience over time

Reduced appetite is often noticeable within the first few weeks. Meaningful weight loss typically becomes apparent at 8 to 12 weeks. Maximum results generally appear at 12 to 18 months of consistent treatment at maintenance dose. Discontinuation is associated with substantial weight regain in most patients within one to two years, reflecting that semaglutide is managing a chronic physiological condition rather than curing it. Long-term planning is part of responsible care.